Expression of sex steroid receptor subtypes in normal and malignant breast tissue – a pilot study in postmenopausal women

Löfgren, Lars; Sahlin, Lena; Schoultz, Bo von; Fernstad, Roland; Skoog, Lambert; Schoultz, E. von

doi:10.1080/02841860500371865

Cited by 10 publications

(8 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the answer to the question as to whether a basal estrogenic milieu ("priming") has an impact on how additive T modulates breast cells, and tissue, respectively, remains speculative [62]. It might be that in an estrogen-deprived milieu (postmenopause) with an increased estrogen receptor expression in normal breast tissue in comparison to premenopausal breast tissue [63]. T is rapidly aromatized to E2 (and not artificially inhibited like in our study).…”

Section: Discussionmentioning

confidence: 75%

Effect of testosterone on E1S-sulfatase activity in non-malignant and cancerous breast cells in vitro

Götte¹,

Kalkhake²,

Ploeger³

et al. 2009

The Journal of Steroid Biochemistry and Molecular Biology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 75%

Effect of testosterone on E1S-sulfatase activity in non-malignant and cancerous breast cells in vitro

Götte¹,

Kalkhake²,

Ploeger³

et al. 2009

The Journal of Steroid Biochemistry and Molecular Biology

View full text Add to dashboard Cite

“…These biological studies provide evidence that PR‐B may stimulate mammary cell growth in the absence or presence of ligand activation, thus contributing to cancer development. Expression of PR‐A and PR‐B is about equal in the normal breast; however, there appears to be dysregulation of this ratio with breast cancer development 15, 45, 46. In addition, Hopp et al 45 reported that patients with a high PR‐A to PR‐B ratio are more likely to relapse.…”

Section: Discussionmentioning

confidence: 99%

+331G/A variant in the progesterone receptor gene, postmenopausal hormone use and risk of breast cancer

Kotsopoulos

Tworoger

DeVivo

et al. 2009

Intl Journal of Cancer

View full text Add to dashboard Cite

A functional promoter polymorphism in the progesterone receptor (PR) gene previously has been associated with an increased risk of postmenopausal breast cancer. Whether the relationship between genetic variation in PR and risk of breast cancer is modified by postmenopausal hormone (PMH) use is unknown. Thus, we conducted a case-control study nested within the prospective Nurses' Health Study to evaluate if the risk of breast cancer associated with having the 1331 A risk allele was modified by PMH use. Genotyping of this SNP was available for 1,664 postmenopausal breast cancer cases and 2,391 controls. Logistic regression was used to estimate the odds ratios (ORs) and 95% confidence intervals (CIs) for breast cancer. Women who were carriers of 1 or both variant A alleles had a 31% increased risk of developing breast cancer (95% CI 1.04-1.65). PMH use significantly modified the association between the 1331G/A polymorphism and risk (pinteraction <0.05). Among never users of PMH, women who were variant carriers had a significantly increased risk of breast cancer compared to those with the wild-type genotype (OR 5 2.57; 95% CI 1.64-4.02). The 1331G/A polymorphism was not associated with breast cancer risk among past (OR 5 1.23; 95% CI 0.77-1.97) or current (OR 5 1.14; 95% CI 0.84-1.56) PMH users. The data from this large prospective study provide evidence for a 2-fold increased risk of developing postmenopausal breast cancer among never users of PMH with the 1331G/A SNP. This finding adds to the evidence that the PR has an important etiologic role in breast cancer and should be evaluated in future studies. ' 2009 UICC

show abstract

“…Comparison of IRS of PGRMC1 and pPGRMC1 with IRS of ERα, PR, total ERβ, Ki-67 and HER2/neu revealed a significant correlation of PGRMC1 and pPGRMC1 expression solely with ERβ expression. Interestingly, most clinical studies found that high expression of ERβ-like proteins is associated with a better clinical outcome although some studies do suggest otherwise [43][44][45].…”

Section: Discussionmentioning

confidence: 99%

High Level of Progesteron Receptor Membrane Component 1 (PGRMC 1) in Tissue of Breast Cancer Patients is Associated with Worse Response to Anthracycline-Based Neoadjuvant Therapy

et al. 2017

View full text Add to dashboard Cite

PGRMC1 is known to be highly expressed in breast cancer tissue and is associated with chemoresistance in breast cancer cells. However, its role in breast cancer signaling is not fully understood yet. In the present study, the expression status of PGRMC1 and its phosphorylated version (pPGRMC1) in breast cancer tissue and surrounding stroma before and after neoadjuvant therapy was examined to find a possible association to therapy response. Tissue biopsies of 69 breast cancer patients were analyzed by immunohistochemistry for expression levels of PGRMC1 and pPGRMC1. Expression status of PGRMC1 and pPGRMC1 in tumor tissue was compared with expression status of progesterone receptor (PR), estrogen receptor α (ERα), total estrogen receptor β (ERβ), ERβ1, ERβ2, the proliferation marker Ki-67, and human epidermal growth factor receptor 2 (HER2/neu). Correlations were calculated for expression of PGRMC1 and pPGRMC1 before and after neoadjuvant-therapy. PGRMC1 and pPGRMC1 were highly abundant in every breast cancer tissue sample. Considerably lower signals were detected in surrounding tissue. Further, PGRMC1 and pPGRMC1 abundance was found to correlate with ERβ expression. A lower level of pPGRMC1 could be found in post-therapy surgical specimens compared to specimens before treatment. Interestingly, patients with high PGRMC1 tumor levels showed worse response to anthracycline-based therapy as patients with lower PGRMC1 levels. These new findings demonstrate that PGRMC1 might play an important role in progression and therapy resistance of human breast tumors and could offer an interesting target for anticancer therapy.

show abstract

Expression of sex steroid receptor subtypes in normal and malignant breast tissue – a pilot study in postmenopausal women

Cited by 10 publications

References 31 publications

Effect of testosterone on E1S-sulfatase activity in non-malignant and cancerous breast cells in vitro

Effect of testosterone on E1S-sulfatase activity in non-malignant and cancerous breast cells in vitro

+331G/A variant in the progesterone receptor gene, postmenopausal hormone use and risk of breast cancer

High Level of Progesteron Receptor Membrane Component 1 (PGRMC 1) in Tissue of Breast Cancer Patients is Associated with Worse Response to Anthracycline-Based Neoadjuvant Therapy

Contact Info

Product

Resources

About